Companies/VYNE Therapeutics Inc.

Company profile

VYNE Therapeutics Inc.

NASDAQ: VYNE · Healthcare · Biotechnology

PublicHQ Bridgewater, NJCIK 0001566044Reports USD

#918 of 1,394 Healthcare companies by revenue60th-percentile growth

EA Score

38D

FH 33DQ 36GM 56SS 40

v0.1 · 65/100 weight · provisional

↑ balance-sheet leverage, revenue growth (YoY) · ↓ operating margin, net margin

Methodology →

Revenue TTM

$454.0k

Rev growth YoY (TTM)

-25.0%

Net income (FY)

-$26.5M

Employees

Market cap

$11.3M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$570.0k$570.0k2025

Net income-$26.5M-$26.5M2025

Operating income-$29.7M-$29.7M2025

Total assets$30.2M$30.2M2025

Liabilities$2.4M$2.4M2025

Equity$27.8M$27.8M2025

Revenue trend

FY2020 – FY2025 · USD

$11.7M

FY20

$3.3M

FY20

$21.0M

FY20

$14.8M

FY21

$477.0k

FY22

$424.0k

FY23

$501.0k

FY24

$570.0k

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Reportable100%

By geography

Not disclosed.

The read

VYNE Therapeutics Inc. booked $570.0k in FY2025 revenue, growing 14% year over year — faster than most Healthcare companies we track, at a -4646.1% net margin.

Peers · Healthcare

Lexaria Bioscience Corp.43D Avicanna Inc.54D Cadrenal Therapeutics, Inc. Common Stock——Phio Pharmaceuticals Corp.40D

Key facts

CEODavid T. Domzalski

SectorHealthcare

IndustryBiotechnology

HeadquartersBridgewater, NJ

ExchangeNASDAQ: VYNE

Employees13

IPO date2018-01-25

Latest filings

8-K2026-07-10 8-K2026-05-21 10-Q2026-05-15 8-K2026-03-11 10-K2026-02-27 8-K2026-01-30 8-K2025-12-17 8-K2025-12-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.